CN1307177C - 伐昔洛韦的合成与纯化 - Google Patents

伐昔洛韦的合成与纯化 Download PDF

Info

Publication number
CN1307177C
CN1307177C CNB028268970A CN02826897A CN1307177C CN 1307177 C CN1307177 C CN 1307177C CN B028268970 A CNB028268970 A CN B028268970A CN 02826897 A CN02826897 A CN 02826897A CN 1307177 C CN1307177 C CN 1307177C
Authority
CN
China
Prior art keywords
valacyclovir
valaciclovir hydrochlordide
deprotection
carbodiimide
acyclovir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028268970A
Other languages
English (en)
Chinese (zh)
Other versions
CN1612878A (zh
Inventor
M·Y·埃廷格尔
L·M·于多维奇
M·于泽福维奇
G·A·尼斯内维奇
B·Z·多利茨基
B·佩尔特西科夫
B·蒂辛
D·布拉斯博格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of CN1612878A publication Critical patent/CN1612878A/zh
Application granted granted Critical
Publication of CN1307177C publication Critical patent/CN1307177C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
CNB028268970A 2001-11-14 2002-11-13 伐昔洛韦的合成与纯化 Expired - Fee Related CN1307177C (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US33280201P 2001-11-14 2001-11-14
US60/332,802 2001-11-14
US34227301P 2001-12-21 2001-12-21
US60/342,273 2001-12-21
PCT/US2002/036269 WO2003041647A2 (en) 2001-11-14 2002-11-13 Synthesis and purification of valacyclovir

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN 200610095946 Division CN1896077A (zh) 2001-11-14 2002-11-13 伐昔洛韦的合成与纯化

Publications (2)

Publication Number Publication Date
CN1612878A CN1612878A (zh) 2005-05-04
CN1307177C true CN1307177C (zh) 2007-03-28

Family

ID=26988392

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028268970A Expired - Fee Related CN1307177C (zh) 2001-11-14 2002-11-13 伐昔洛韦的合成与纯化

Country Status (14)

Country Link
US (2) US6849737B2 (cg-RX-API-DMAC7.html)
EP (1) EP1465894A4 (cg-RX-API-DMAC7.html)
JP (1) JP2005508993A (cg-RX-API-DMAC7.html)
KR (2) KR20050044449A (cg-RX-API-DMAC7.html)
CN (1) CN1307177C (cg-RX-API-DMAC7.html)
CA (2) CA2649826A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20040511A2 (cg-RX-API-DMAC7.html)
IL (1) IL161969A0 (cg-RX-API-DMAC7.html)
IN (1) IN2007DE04250A (cg-RX-API-DMAC7.html)
IS (1) IS7260A (cg-RX-API-DMAC7.html)
MX (1) MX242714B (cg-RX-API-DMAC7.html)
NO (1) NO20042433L (cg-RX-API-DMAC7.html)
PL (1) PL371732A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003041647A2 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL374179A1 (en) * 2001-09-07 2005-10-03 Teva Pharmaceutical Industries Ltd. Crystalline forms of valacyclovir hydrochloride
JP2005511612A (ja) * 2001-11-05 2005-04-28 グラクソ　グループ　リミテッド 塩酸バラシクロビルの無水結晶形
IL161969A0 (en) * 2001-11-14 2005-11-20 Teva Pharma Synthesis and purification of valacyclovir
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
AU2003277433A1 (en) * 2002-10-16 2004-05-04 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
WO2004052892A1 (en) * 2002-12-09 2004-06-24 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
EP1633753A1 (en) * 2003-05-30 2006-03-15 EOS Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ti Caret A.S. Novel crystalline forms of valacyclovir hydrochloride
KR100871621B1 (ko) * 2003-06-02 2008-12-02 테바 파마슈티컬 인더스트리즈 리미티드 발라시클로비르 히드로클로라이드의 신규한 결정질 형태
KR20060117355A (ko) * 2004-01-21 2006-11-16 테바 파마슈티컬 인더스트리즈 리미티드 발라시클로버 염산염의 제조 방법
CA2572268A1 (en) * 2004-06-30 2006-02-02 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
CN101068814A (zh) * 2004-09-04 2007-11-07 特瓦制药工业有限公司 分离的伐昔洛韦杂质，制备伐昔洛韦杂质的方法及其作为参比标准物的应用
US7958087B2 (en) * 2004-11-17 2011-06-07 Iron Mountain Incorporated Systems and methods for cross-system digital asset tag propagation
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process
GB0605344D0 (en) * 2006-03-17 2006-04-26 Pliva Istrazivanje I Razvoj D Pharmaceutically acceptable salts and polymorphic forms
CN1903854B (zh) * 2006-08-09 2012-05-23 丽珠医药集团股份有限公司 一种合成盐酸伐昔洛韦的方法
WO2008139539A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. バラシクロビルの製造方法
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof
CN102584825B (zh) * 2011-01-17 2014-04-02 四川科伦药物研究有限公司 一种合成盐酸伐昔洛韦的方法
WO2017149420A1 (en) * 2016-03-03 2017-09-08 Aurobindo Pharma Ltd Process for the preparation of valacyclovir
CN106632335A (zh) * 2016-12-27 2017-05-10 河南康达制药有限公司 一种盐酸伐昔洛韦的制备方法
CN114621227B (zh) * 2022-02-28 2024-07-09 海南久常制药有限公司 一种盐酸伐昔洛韦、制剂及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997025989A1 (en) * 1996-01-19 1997-07-24 Glaxo Group Limited Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application
WO1998003553A1 (en) * 1996-07-18 1998-01-29 Industriale Chimica S.R.L. Process of preparation of valacyclovir and relevant intermediates
US6107302A (en) * 1995-01-20 2000-08-22 Glaxo Wellcome Inc. Guanine derivative
US6218568B1 (en) * 1996-01-26 2001-04-17 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199574A (en) 1974-09-02 1980-04-22 Burroughs Wellcome Co. Methods and compositions for treating viral infections and guanine acyclic nucleosides
GB8719367D0 (en) 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
ATE199719T1 (de) * 1993-06-10 2001-03-15 Rolabo Sl Verfahren zur herstellung von aminosäureester von nukleosid analogen
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
US6117453A (en) * 1995-04-14 2000-09-12 Pharma Pass Solid compositions containing polyethylene oxide and an active ingredient
US5672243A (en) * 1995-11-28 1997-09-30 Mosel Vitelic, Inc. Antireflection coating for highly reflective photolithographic layers comprising chromium oxide or chromium suboxide
US5756736A (en) * 1996-01-26 1998-05-26 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
AU735438B2 (en) * 1996-11-12 2001-07-05 Medivir Ab Nucleosides
PL374179A1 (en) * 2001-09-07 2005-10-03 Teva Pharmaceutical Industries Ltd. Crystalline forms of valacyclovir hydrochloride
JP2005511612A (ja) * 2001-11-05 2005-04-28 グラクソ　グループ　リミテッド 塩酸バラシクロビルの無水結晶形
IL161969A0 (en) * 2001-11-14 2005-11-20 Teva Pharma Synthesis and purification of valacyclovir
US20060147519A1 (en) * 2002-06-24 2006-07-06 Ashish Gogia Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
AU2003277433A1 (en) * 2002-10-16 2004-05-04 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
WO2004052892A1 (en) * 2002-12-09 2004-06-24 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
EP1633753A1 (en) * 2003-05-30 2006-03-15 EOS Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ti Caret A.S. Novel crystalline forms of valacyclovir hydrochloride
KR100871621B1 (ko) * 2003-06-02 2008-12-02 테바 파마슈티컬 인더스트리즈 리미티드 발라시클로비르 히드로클로라이드의 신규한 결정질 형태
KR20060117355A (ko) * 2004-01-21 2006-11-16 테바 파마슈티컬 인더스트리즈 리미티드 발라시클로버 염산염의 제조 방법
US20060178512A1 (en) * 2005-02-04 2006-08-10 Cheruthur Govindan Method for preparing amino acid esters of nucleoside analogues
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107302A (en) * 1995-01-20 2000-08-22 Glaxo Wellcome Inc. Guanine derivative
WO1997025989A1 (en) * 1996-01-19 1997-07-24 Glaxo Group Limited Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application
US6218568B1 (en) * 1996-01-26 2001-04-17 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
WO1998003553A1 (en) * 1996-07-18 1998-01-29 Industriale Chimica S.R.L. Process of preparation of valacyclovir and relevant intermediates

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
盐酸伐昔洛韦 张征，中国抗生素杂志，第24卷第2期 1999 *

Also Published As

Publication number Publication date
MX242714B (es) 2006-12-15
CA2465928C (en) 2010-01-19
JP2005508993A (ja) 2005-04-07
KR20070020149A (ko) 2007-02-16
US20050130993A1 (en) 2005-06-16
US20030153757A1 (en) 2003-08-14
IL161969A0 (en) 2005-11-20
WO2003041647A3 (en) 2003-11-20
KR20050044449A (ko) 2005-05-12
WO2003041647A2 (en) 2003-05-22
EP1465894A4 (en) 2008-10-08
PL371732A1 (en) 2005-06-27
IS7260A (is) 2004-05-11
NO20042433L (no) 2004-07-22
HRP20040511A2 (en) 2004-10-31
CA2465928A1 (en) 2003-05-22
IN2007DE04250A (cg-RX-API-DMAC7.html) 2007-08-31
CN1612878A (zh) 2005-05-04
EP1465894A2 (en) 2004-10-13
MXPA04004656A (es) 2004-08-13
CA2649826A1 (en) 2003-05-22
US6849737B2 (en) 2005-02-01

Similar Documents

Publication Publication Date Title
CN1307177C (zh) 伐昔洛韦的合成与纯化
US20110021567A1 (en) Preparation of lenalidomide
KR100774271B1 (ko) 발라사이클로비르 염산염의 결정질 형태
EP4328226A1 (en) Tolebrutinib crystal form, amorphous form, preparation method therefor and use thereof
CN101772491A (zh) 基本不含有二聚体杂质的瑞格列奈
US20050043329A1 (en) Crystalline forms of valacyclovir hydrochloride
EP2014660A2 (en) Novel crystalline forms of valacyclovir hydrochloride
WO2004106338A1 (en) Novel crystalline forms of valacyclovir hydrochloride
EA014101B1 (ru) Антагонист cd80
EP2938603A1 (en) Cobicostat dichlohydrate salt
JP2003519695A (ja) ピリミジンベースの抗ウイルス剤のアリールスルホン酸塩
ZA200403544B (en) Synthesis and purification of valacyclovir.
AU2002359384A1 (en) Synthesis and purification of valacyclovir
HUP0401981A2 (hu) Valacyclovir szintézise és tisztítása
RS54855B1 (sr) Soli perindoprila
EP1473036B1 (en) Zolpidem hemitartrate solvate
WO2023222946A1 (en) Process for the preparation of cabozantinib
CN110167932A (zh) 用于制备(3S，4S)-4-异丙基-6，7-二氢-3H-咪唑并[4，5-c]吡啶-5(4H)-羧酸四氢呋喃-3-基酯的方法
CN1694884A (zh) Ⅰ晶型、ⅱ晶型、ⅲ晶型泛昔洛韦及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee